The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Kvaterin     3-(trimethylammonioamino) propanoate

Synonyms: Quaterin, Meldomiun, Meldonium, Mildronate, MET88, ...
This record was replaced with 123869.
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of (2-carboxyethylamino)-trimethyl-azanium

 

High impact information on (2-carboxyethylamino)-trimethyl-azanium

 

Chemical compound and disease context of (2-carboxyethylamino)-trimethyl-azanium

 

Biological context of (2-carboxyethylamino)-trimethyl-azanium

 

Anatomical context of (2-carboxyethylamino)-trimethyl-azanium

 

Associations of (2-carboxyethylamino)-trimethyl-azanium with other chemical compounds

 

Analytical, diagnostic and therapeutic context of (2-carboxyethylamino)-trimethyl-azanium

References

  1. Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction. Liepinsh, E., Vilskersts, R., Loca, D., Kirjanova, O., Pugovichs, O., Kalvinsh, I., Dambrova, M. J. Cardiovasc. Pharmacol. (2006) [Pubmed]
  2. Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics. Sesti, C., Simkhovich, B.Z., Kalvinsh, I., Kloner, R.A. J. Cardiovasc. Pharmacol. (2006) [Pubmed]
  3. Mildronate: cardioprotective action through carnitine-lowering effect. Dambrova, M., Liepinsh, E., Kalvinsh, I. Trends Cardiovasc. Med. (2002) [Pubmed]
  4. Carnitine transport into muscular cells. Inhibition of transport and cell growth by mildronate. Georges, B., Le Borgne, F., Galland, S., Isoir, M., Ecosse, D., Grand-Jean, F., Demarquoy, J. Biochem. Pharmacol. (2000) [Pubmed]
  5. Endothelium- and nitric oxide-dependent vasorelaxing activities of gamma-butyrobetaine esters: possible link to the antiischemic activities of mildronate. Sjakste, N., Kleschyov, A.L., Boucher, J.L., Baumane, L., Dzintare, M., Meirena, D., Sjakste, J., Sydow, K., Münzel, T., Kalvinsh, I. Eur. J. Pharmacol. (2004) [Pubmed]
  6. Carnitine depletion in rat pups from mothers given mildronate: a model of carnitine deficiency in late fetal and neonatal life. Peschechera, A., Scalibastri, M., Russo, F., Giarrizzo, M.G., Carminati, P., Giannessi, F., Arduini, A., Ricciolini, R. Life Sci. (2005) [Pubmed]
  7. Fatty acid oxidation and related gene expression in heart depleted of carnitine by mildronate treatment in the rat. Degrace, P., Demizieux, L., Gresti, J., Tsoko, M., André, A., Demaison, L., Clouet, P. Mol. Cell. Biochem. (2004) [Pubmed]
  8. Mildronate: an antiischemic drug for neurological indications. Sjakste, N., Gutcaits, A., Kalvinsh, I. CNS drug reviews. (2005) [Pubmed]
  9. Protection of azidothymidine-induced cardiopathology in mice by mildronate, a mitochondria-targeted drug. Klusa, V., Pupure, J., Isajevs, S., Rumaks, J., Gordjushina, V., Kratovska, A., Taivans, I., Svirskis, S., Viksna, L., Kalvinsh, I. Basic & clinical pharmacology & toxicology. (2006) [Pubmed]
  10. Effects of gamma-butyrobetaine and mildronate on nitric oxide production in lipopolysaccharide-treated rats. Sjakste, N., Baumane, L., Boucher, J.L., Dzintare, M., Meirena, D., Sjakste, J., Lauberte, L., Kalvinsh, I. Basic & clinical pharmacology & toxicology. (2004) [Pubmed]
  11. HPLC analysis of mildronate and its analogues in plasma. Sahartova, O., Shatz, V., Kalvins, I. Journal of pharmaceutical and biomedical analysis. (1993) [Pubmed]
  12. Direct chronotropic and inotropic effects of mildronate using cross-circulated dog atrial and ventricular preparations. Chiba, S., Akahane, K., Furukawa, Y., Karasawa, Y. Japanese heart journal. (1989) [Pubmed]
 
WikiGenes - Universities